CN105102442B - 作为抗癌药的喹啉衍生物 - Google Patents
作为抗癌药的喹啉衍生物 Download PDFInfo
- Publication number
- CN105102442B CN105102442B CN201480016433.4A CN201480016433A CN105102442B CN 105102442 B CN105102442 B CN 105102442B CN 201480016433 A CN201480016433 A CN 201480016433A CN 105102442 B CN105102442 B CN 105102442B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- quinoline
- piperidin
- chloro
- diethylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CN(*)C(CC1)CCN1C(*)* Chemical compound CN(*)C(CC1)CCN1C(*)* 0.000 description 6
- OUXRMEUJNPVXMM-UHFFFAOYSA-N CCN(CC)C1CCNCC1 Chemical compound CCN(CC)C1CCNCC1 OUXRMEUJNPVXMM-UHFFFAOYSA-N 0.000 description 3
- PMACRAXEDMRQCH-UHFFFAOYSA-N CC(C)(C)NC(CC1)CCN1c1cc(-c2ccccc2)nc2c1cccc2 Chemical compound CC(C)(C)NC(CC1)CCN1c1cc(-c2ccccc2)nc2c1cccc2 PMACRAXEDMRQCH-UHFFFAOYSA-N 0.000 description 2
- OVNIWCRPJILPRK-UHFFFAOYSA-N CC(c1cc(-c2ccccc2)nc2ccccc12)=O Chemical compound CC(c1cc(-c2ccccc2)nc2ccccc12)=O OVNIWCRPJILPRK-UHFFFAOYSA-N 0.000 description 2
- ZDHWTCRWZQGUIN-UHFFFAOYSA-N CCN(CC)C(CC1)CCN1C(C)c1c(cccc2)c2nc(-c2ccccc2)c1 Chemical compound CCN(CC)C(CC1)CCN1C(C)c1c(cccc2)c2nc(-c2ccccc2)c1 ZDHWTCRWZQGUIN-UHFFFAOYSA-N 0.000 description 2
- LVCVUWIWHULCGT-UHFFFAOYSA-N C(CC1)CCN1C(CC1)CCN1C1=CC(C2C=CC=CC2)=NC2=CCCC=C12 Chemical compound C(CC1)CCN1C(CC1)CCN1C1=CC(C2C=CC=CC2)=NC2=CCCC=C12 LVCVUWIWHULCGT-UHFFFAOYSA-N 0.000 description 1
- BVJLAIOEDPVHLO-UHFFFAOYSA-N C(CC1)CCN1C(CC1)CCN1c1cc(-c2ccccc2)nc2c1cccc2 Chemical compound C(CC1)CCN1C(CC1)CCN1c1cc(-c2ccccc2)nc2c1cccc2 BVJLAIOEDPVHLO-UHFFFAOYSA-N 0.000 description 1
- IINSBGZQDQRBQM-HZVLYBHQSA-N CC(/C=C(\C(\Cl)=C/C)/Cl)/C(/C)=N/C(/C(C(F)(F)F)=C)=C/C=C Chemical compound CC(/C=C(\C(\Cl)=C/C)/Cl)/C(/C)=N/C(/C(C(F)(F)F)=C)=C/C=C IINSBGZQDQRBQM-HZVLYBHQSA-N 0.000 description 1
- QKJSGQLRWYZZSC-UHFFFAOYSA-N CC(C)(C)NC(CC1)CCN1c1cc(-c(cc2)ccc2Cl)nc2c1cccc2 Chemical compound CC(C)(C)NC(CC1)CCN1c1cc(-c(cc2)ccc2Cl)nc2c1cccc2 QKJSGQLRWYZZSC-UHFFFAOYSA-N 0.000 description 1
- RCFFYSMJJFWILQ-UHFFFAOYSA-N CC(C)(C)Oc1cc(-c(cc2Cl)ccc2Cl)nc2c1cccc2 Chemical compound CC(C)(C)Oc1cc(-c(cc2Cl)ccc2Cl)nc2c1cccc2 RCFFYSMJJFWILQ-UHFFFAOYSA-N 0.000 description 1
- RFDALTLXXAUXFI-UHFFFAOYSA-N CC1(c2ccccc2)Nc(cc(C)cc2)c2C(NCCCN(C)C)=C1 Chemical compound CC1(c2ccccc2)Nc(cc(C)cc2)c2C(NCCCN(C)C)=C1 RFDALTLXXAUXFI-UHFFFAOYSA-N 0.000 description 1
- TVSMLBGFGKLKOO-UHFFFAOYSA-N CC1CCN(C)CC1 Chemical compound CC1CCN(C)CC1 TVSMLBGFGKLKOO-UHFFFAOYSA-N 0.000 description 1
- XDARNKSWRIHYEQ-UHFFFAOYSA-N CCN(CC)C1CCN(Cc2cc(-c3ccccc3)nc3c2ccc(C)c3)CC1 Chemical compound CCN(CC)C1CCN(Cc2cc(-c3ccccc3)nc3c2ccc(C)c3)CC1 XDARNKSWRIHYEQ-UHFFFAOYSA-N 0.000 description 1
- JHWXVVLFVOSFNL-UHFFFAOYSA-N CCNCC(C)CCN(C)C(OC(C)(C)C)=O Chemical compound CCNCC(C)CCN(C)C(OC(C)(C)C)=O JHWXVVLFVOSFNL-UHFFFAOYSA-N 0.000 description 1
- GJBRBFOAJXGMMF-UHFFFAOYSA-N CN(C(c1c(cccc2)c2nc(-c2ccccc2)c1)=O)OC Chemical compound CN(C(c1c(cccc2)c2nc(-c2ccccc2)c1)=O)OC GJBRBFOAJXGMMF-UHFFFAOYSA-N 0.000 description 1
- WRXPINFCSQPXSM-UHFFFAOYSA-N CN(C(c1c(cccc2)c2nc(-c2ccccc2)c1)=O)[O](C)C Chemical compound CN(C(c1c(cccc2)c2nc(-c2ccccc2)c1)=O)[O](C)C WRXPINFCSQPXSM-UHFFFAOYSA-N 0.000 description 1
- HVOYZOQVDYHUPF-UHFFFAOYSA-N CNCCN(C)C Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
- AKNGBEPPENYIKS-OAHLLOKOSA-N C[C@H](C=C1)C(C2=NC3=CCCC(CC(C)(C)O)=C3C=C2)=CC=C1OC Chemical compound C[C@H](C=C1)C(C2=NC3=CCCC(CC(C)(C)O)=C3C=C2)=CC=C1OC AKNGBEPPENYIKS-OAHLLOKOSA-N 0.000 description 1
- DXDIVXUXILVANI-UHFFFAOYSA-N NC(CC1)CCN1c1cc(-c2ccccc2)nc2c1cccc2 Chemical compound NC(CC1)CCN1c1cc(-c2ccccc2)nc2c1cccc2 DXDIVXUXILVANI-UHFFFAOYSA-N 0.000 description 1
- AXGVBOGUDLOFHK-UHFFFAOYSA-N NC1C=C(C=C(C=C2)c3ccc(C4C=CC=CC4)cc3)C2=CC1 Chemical compound NC1C=C(C=C(C=C2)c3ccc(C4C=CC=CC4)cc3)C2=CC1 AXGVBOGUDLOFHK-UHFFFAOYSA-N 0.000 description 1
- VBLXCTYLWZJBKA-UHFFFAOYSA-N Nc1ccccc1C(F)(F)F Chemical compound Nc1ccccc1C(F)(F)F VBLXCTYLWZJBKA-UHFFFAOYSA-N 0.000 description 1
- ZAABWVGWUUEMIQ-UHFFFAOYSA-N O=Cc1cc(-c2ccccc2)nc2c1ccc(I)c2 Chemical compound O=Cc1cc(-c2ccccc2)nc2c1ccc(I)c2 ZAABWVGWUUEMIQ-UHFFFAOYSA-N 0.000 description 1
- WVUJVQGSMRAXJG-UHFFFAOYSA-N O=Cc1cc(-c2ccccc2)nc2c1cccc2 Chemical compound O=Cc1cc(-c2ccccc2)nc2c1cccc2 WVUJVQGSMRAXJG-UHFFFAOYSA-N 0.000 description 1
- ODWRVCWITIGQHX-UHFFFAOYSA-N OC(c1cc(-c2ccccc2)cc2c1cccc2)=O Chemical compound OC(c1cc(-c2ccccc2)cc2c1cccc2)=O ODWRVCWITIGQHX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/18—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361802891P | 2013-03-18 | 2013-03-18 | |
| US61/802,891 | 2013-03-18 | ||
| PCT/IL2014/050273 WO2014147611A1 (en) | 2013-03-18 | 2014-03-13 | Quinolines derivatives as novel anticancer agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105102442A CN105102442A (zh) | 2015-11-25 |
| CN105102442B true CN105102442B (zh) | 2018-11-09 |
Family
ID=51579387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480016433.4A Expired - Fee Related CN105102442B (zh) | 2013-03-18 | 2014-03-13 | 作为抗癌药的喹啉衍生物 |
Country Status (13)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1217092A1 (zh) | 2013-02-15 | 2016-12-23 | Kala Pharmaceuticals, Inc. | 治疗性化合物及其用途 |
| ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| SMT201700442T1 (it) * | 2013-09-16 | 2017-11-15 | Astrazeneca Ab | Nanoparticelle polimeriche terapeutiche e metodi per preparare e usare le stesse |
| KR20160099084A (ko) | 2013-11-01 | 2016-08-19 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정질 형태 및 그의 용도 |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| JP2016538306A (ja) * | 2013-11-27 | 2016-12-08 | アメリカ合衆国 | 複素環化合物及びその使用方法 |
| CA2964113A1 (en) * | 2014-10-14 | 2016-04-21 | La Jolla Institute Of Allergy & Immunology | Inhibitors of low molecular weight protein tyrosine phosphatase and uses thereof |
| PT3212629T (pt) * | 2014-10-31 | 2019-02-04 | Genoscience Pharma Sas | Substituído 2,4 diamino-quinoline como novos agentes anti cancro |
| BR112018008630A2 (pt) | 2015-11-06 | 2018-10-30 | Neurocrine Biosciences Inc | derivados de n-[2-(1-benzilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazina-1-carboxamida, seus usos, composição farmacêutica |
| EA039638B1 (ru) * | 2016-01-06 | 2022-02-21 | Нейрокрин Байосайенсиз, Инк. | Антагонисты мускаринового рецептора 4 и способы их применения |
| WO2017136451A1 (en) * | 2016-02-01 | 2017-08-10 | Regenacy Pharmaceuticals, Llc | Hdac1/2 inhibitors for the treatment of neurodegenerative and/or cognitive disorders |
| SI3452465T1 (sl) * | 2016-05-04 | 2021-04-30 | Genoscience Pharma | Substituirani derivati 2,4-diamino-kinolina za uporabo v zdravljenju proliferativnih bolezni |
| CN106008339B (zh) * | 2016-06-08 | 2018-09-07 | 上海准视生物科技有限公司 | 一种放射性c-met靶向亲和小分子化合物及其应用 |
| KR20190051010A (ko) | 2016-09-08 | 2019-05-14 | 칼라 파마슈티컬스, 인크. | 치료 화합물의 결정형 및 그의 용도 |
| US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| EP4275759B1 (en) | 2016-09-26 | 2025-12-24 | Dana-Farber Cancer Institute, Inc. | Quinoline derivatives as chromobox (cbx) protein inhibitors for treating cancer |
| CN106619633B (zh) * | 2016-12-16 | 2019-05-31 | 江苏大学 | Fpthq在制备治疗卵巢癌的药物中的应用 |
| CN106619634B (zh) * | 2016-12-16 | 2019-05-31 | 江苏大学 | 化合物4-bpt在制备治疗卵巢癌药物中的应用 |
| CN106727559B (zh) * | 2016-12-16 | 2019-05-31 | 江苏大学 | 7-mdt在制备治疗卵巢癌的药物中的应用 |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| EP3619210A4 (en) | 2017-05-01 | 2020-12-02 | Sanford Burnham Prebys Medical Discovery Institute | LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) INHIBITORS AND ASSOCIATED USES |
| US11065265B2 (en) | 2018-05-18 | 2021-07-20 | Spes Pharmaceuticals Inc. | Compositions of fosaprepitant and methods of preparation |
| CN110437149B (zh) * | 2019-08-20 | 2021-01-29 | 大连民族大学 | 抗肿瘤活性的天然萘基异喹啉类化合物及其组合物、应用 |
| EP4017492A4 (en) * | 2019-08-22 | 2023-10-11 | Biohaven Therapeutics Ltd. | MOLECULES THAT BIND TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS |
| ES2983860T3 (es) | 2019-12-06 | 2024-10-25 | Neurocrine Biosciences Inc | Antagonistas del receptor muscarínico 4 y métodos de uso |
| CN115108977B (zh) * | 2021-03-19 | 2024-11-29 | 南京正大天晴制药有限公司 | 一种瑞戈非尼的制备方法 |
| CN113999206B (zh) * | 2021-12-31 | 2022-04-12 | 北京鑫开元医药科技有限公司 | 异喹啉-1,3-二胺类似物、制备方法、药物组合物及其应用 |
| CN114533733A (zh) * | 2021-12-31 | 2022-05-27 | 北京鑫开元医药科技有限公司 | 一种异喹啉-1,3-二胺类似物药物制剂及其制备方法 |
| CN115745889B (zh) * | 2022-12-07 | 2025-03-14 | 中国人民解放军空军军医大学 | 一类含有2-芳基-4-取代喹啉结构的化合物及其制备方法与应用 |
| CN118164954B (zh) * | 2024-03-13 | 2024-09-27 | 江苏蒙博生物工程科技有限公司 | 一种基于10-羟基苯并[h]喹啉荧光母核的荧光探针、制备方法与应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560692A (en) * | 1984-07-18 | 1985-12-24 | Hoffmann-La Roche Inc. | 4-Piperidino-2-phenylquinolines |
| WO1998057931A2 (en) * | 1997-06-19 | 1998-12-23 | Sepracor Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| WO2005061519A1 (en) * | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| WO2006094237A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Acridine and quinoline dervatives as sirtuin modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1886781A (en) * | 1932-11-08 | Multiplying mechanism for calculating machines | ||
| US1886481A (en) | 1927-11-07 | 1932-11-08 | Soc Of Chemical Ind | Unilaterally acylated diamines and process of making same |
| JPH02129169A (ja) * | 1988-11-08 | 1990-05-17 | Ube Ind Ltd | キノリン化合物およびその医薬用途 |
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| AU6051800A (en) * | 1999-06-16 | 2001-01-02 | University Of Iowa Research Foundation, The | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
| SE9902987D0 (sv) * | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| EA200400980A1 (ru) * | 2002-02-27 | 2005-02-24 | Пфайзер Продактс Инк. | Ингибиторы асс |
| US20100150844A1 (en) | 2006-07-28 | 2010-06-17 | The Johns Hopkins University | Use of 8-quinolinol and its analogs to target cancer stem cells |
| WO2011130677A1 (en) | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Inhibitors of cancer stem cells |
-
2014
- 2014-03-13 US US14/777,917 patent/US10179770B2/en not_active Expired - Fee Related
- 2014-03-13 AU AU2014233757A patent/AU2014233757B2/en not_active Ceased
- 2014-03-13 JP JP2016503776A patent/JP2016519091A/ja active Pending
- 2014-03-13 BR BR112015023948A patent/BR112015023948A2/pt not_active IP Right Cessation
- 2014-03-13 WO PCT/IL2014/050273 patent/WO2014147611A1/en not_active Ceased
- 2014-03-13 KR KR1020157026114A patent/KR20150132192A/ko not_active Ceased
- 2014-03-13 MX MX2015013396A patent/MX2015013396A/es unknown
- 2014-03-13 CA CA2902734A patent/CA2902734A1/en not_active Abandoned
- 2014-03-13 NZ NZ710854A patent/NZ710854A/en not_active IP Right Cessation
- 2014-03-13 EP EP14770929.9A patent/EP2976333B1/en not_active Not-in-force
- 2014-03-13 CN CN201480016433.4A patent/CN105102442B/zh not_active Expired - Fee Related
- 2014-03-13 SG SG11201506385WA patent/SG11201506385WA/en unknown
-
2015
- 2015-09-16 ZA ZA2015/06880A patent/ZA201506880B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560692A (en) * | 1984-07-18 | 1985-12-24 | Hoffmann-La Roche Inc. | 4-Piperidino-2-phenylquinolines |
| WO1998057931A2 (en) * | 1997-06-19 | 1998-12-23 | Sepracor Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| WO2005061519A1 (en) * | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
| WO2006094237A2 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Acridine and quinoline dervatives as sirtuin modulators |
Non-Patent Citations (3)
| Title |
|---|
| "FURTHER INVESTIGATIONS OF HETEROCYCLIC ALKYLATING AGENTS";RK Preston等;《Journal of Medicinal Chemistry》;19640731;第7卷;第471、473页 * |
| "Mono- and Difunctional Analogs of Some Quinoline and Acridine Nitrogen Mustards1";RM Peck等;《Journal of Organic Chemistry》;19610930;第26卷;第3409、3411页 * |
| "Oxadiazoles as bioisosteric transformations of carboxylic functionalities. II";KE Andersen等;《Eur. J. Med. Chem.》;19961231;第31卷;第421页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201506385WA (en) | 2015-10-29 |
| EP2976333A4 (en) | 2016-08-31 |
| NZ710854A (en) | 2019-06-28 |
| EP2976333B1 (en) | 2018-08-08 |
| CA2902734A1 (en) | 2014-09-25 |
| US20160280653A1 (en) | 2016-09-29 |
| MX2015013396A (es) | 2016-07-08 |
| EP2976333A1 (en) | 2016-01-27 |
| US10179770B2 (en) | 2019-01-15 |
| BR112015023948A2 (pt) | 2017-07-18 |
| AU2014233757A1 (en) | 2015-08-27 |
| WO2014147611A1 (en) | 2014-09-25 |
| ZA201506880B (en) | 2019-12-18 |
| CN105102442A (zh) | 2015-11-25 |
| JP2016519091A (ja) | 2016-06-30 |
| AU2014233757B2 (en) | 2017-12-21 |
| WO2014147611A8 (en) | 2014-11-20 |
| KR20150132192A (ko) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105102442B (zh) | 作为抗癌药的喹啉衍生物 | |
| JP7667160B2 (ja) | Ｋｒａｓの阻害剤としての三環式化合物 | |
| JP7401651B2 (ja) | がんの治療における使用のためのヘテロ環式化合物 | |
| CN110267953B (zh) | 四氢咪唑并[4,5-c]吡啶衍生物作为pd-l1内在化诱导剂 | |
| CN107922388B (zh) | 用于抑制shp2活性的化合物和组合物 | |
| TWI657083B (zh) | 用於抑制ｓｈｐ２活性之化合物及組合物 | |
| CN103102344B (zh) | 氨基喹唑啉类衍生物及其盐和使用方法 | |
| CN115697999A (zh) | 杂环glp-1激动剂 | |
| EP4232445A1 (en) | Compounds and methods for the targeted degradation of androgen receptor protein | |
| WO2017197056A1 (en) | Bromodomain targeting degronimers for target protein degradation | |
| JP7239562B2 (ja) | 光学活性な架橋型環状２級アミン誘導体 | |
| CN109562113A (zh) | 用于靶蛋白降解的螺环降解决定子体 | |
| JP6972384B2 (ja) | 複素環化合物 | |
| EP2681215A1 (en) | Serine/threonine kinase inhibitors | |
| WO2014151936A1 (en) | Octahydropyrrolopyrroles, their preparation and use | |
| CN105518001A (zh) | Bet蛋白抑制性的改性的二氢喹喔啉酮类化合物和二氢吡啶并吡嗪酮类化合物 | |
| EP3617195A1 (en) | Novel tetrahydronaphthyl urea derivatives | |
| CN103102342A (zh) | 氨基喹唑啉类衍生物及其盐和使用方法 | |
| CN115636833A (zh) | 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途 | |
| JP2022548618A (ja) | Ｍｌｌ１阻害剤及び抗癌剤 | |
| TWI862653B (zh) | 雜環化合物 | |
| HK40057282B (zh) | 蛋白质酪氨酸磷酸酶抑制剂 | |
| WO2024125551A1 (zh) | 细胞周期蛋白k降解剂及其应用 | |
| KR20250145679A (ko) | Ret 키나제의 분해제로서의 이소인돌리논 글루타르이미드 및 페닐 글루타르이미드 유사체 | |
| CN117730080A (zh) | 吡啶并嘧啶酮类衍生物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20181109 Termination date: 20200313 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |